SCHEDULE: Fairmount Funds Boost Stake in Crescent Biopharma

Fairmount Funds Management LLC and its affiliates have increased their beneficial ownership in Crescent Biopharma, Inc. to 16.52% through recent share and warrant purchases.

Summary

• Fairmount Funds Management LLC and its affiliates have filed an amendment to their Schedule 13D, increasing their beneficial ownership in Crescent Biopharma, Inc.
• The total beneficial ownership now stands at 6,602,408 Ordinary Shares, representing approximately 16.52% of the outstanding shares.
• This increase is due to the purchase of 853,450 Ordinary Shares and Pre-Funded Warrants to purchase up to 525,897 Ordinary Shares in an underwritten public offering on July 16, 2026.
• The total purchase price for these securities was $20,000,005.60, funded by working capital.
• The filing also notes beneficial ownership limitations: 9.99% for Pre-Funded Warrants and 19.99% for Series A Preferred Shares, which can adjust under certain conditions.
• A lock-up agreement is in place, restricting the sale of company securities for 60 days following the offering's final prospectus supplement.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting increased investment and stake by a significant fund, but also highlighting ownership limitations and a lock-up period.

Positives

• Increased investment by Fairmount Funds Management LLC and its affiliates, indicating confidence in Crescent Biopharma.
• Acquisition of 853,450 Ordinary Shares and Pre-Funded Warrants in a public offering, demonstrating active participation in the company's capital markets.
• The purchase was made with working capital, suggesting no immediate need for external financing for this specific transaction.

Negatives

• The beneficial ownership limitations (9.99% for warrants, 19.99% for preferred shares) may restrict future exercise or conversion of these securities.
• A 60-day lock-up agreement restricts the reporting persons from selling securities, potentially limiting their immediate flexibility.

Risks

• Beneficial ownership limitations could prevent the full exercise of warrants or conversion of preferred shares if ownership exceeds the specified thresholds.
• The lock-up agreement restricts the ability to sell shares for 60 days, posing a risk if market conditions change unfavorably during this period.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from the company itself, but rather details the investment activities and holdings of Fairmount Funds Management LLC and its affiliates.

Management Comments

• The securities include (a) 3,601,316 Ordinary Shares, 2,890,000 Ordinary Shares issuable upon conversion of 2,890 Series A Preferred Shares, and 102,069 Ordinary Shares issuable upon exercise of Pre-Funded Warrants directly held by Fund II and exclude (b) 2,191,968 Ordinary Shares issuable upon exercise of Pre-Funded Warrants, due to the application of the beneficial ownership limitation.
• The exercise of the Pre-Funded Warrants is subject to a beneficial ownership limitation of 9.99% of the outstanding Ordinary Shares and the exercise of the Series A Preferred Shares is subject to a beneficial ownership limitation of 19.99%.
• At such time as Fairmount and its affiliates beneficially own 9.0% or less of the Ordinary Shares, the beneficial ownership limitation with respect to the Series A Preferred Shares will automatically reduce to 9.99%.
• Mr. Harwin holds the options for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock.

Industry Context

StockSavvy.ai notes that this Schedule 13D filing by Fairmount Funds Management LLC indicates a significant investment in Crescent Biopharma, Inc. Such filings are common when institutional investors cross certain ownership thresholds, signaling active management and potential influence over the company's strategic direction. The details provided on warrant and preferred share limitations are crucial for understanding the precise nature of control and potential dilution.

Stakeholder Impact

• Shareholders: The increased stake by Fairmount Funds may signal increased institutional interest, but the beneficial ownership limitations and lock-up period could affect immediate market dynamics.
• Creditors: No direct impact mentioned, but increased institutional ownership can sometimes correlate with improved financial oversight.
• Employees: No direct impact mentioned.

Next Steps

• The reporting persons are subject to a 60-day lock-up agreement, restricting sales of company securities.
• The beneficial ownership limitations on warrants and preferred shares may be adjusted based on future ownership levels.

Key Dates

Recommendation

The filing indicates increased investment by a significant fund, which is generally positive. However, the presence of beneficial ownership limitations and a 60-day lock-up period suggests a cautious approach is warranted. The filing itself does not provide operational or financial performance updates for Crescent Biopharma, making a definitive buy/sell recommendation difficult without further context on the company's underlying business.

Keywords

Crescent Biopharma, Schedule 13D, Fairmount Funds Management, Beneficial Ownership, Ordinary Shares, Pre-Funded Warrants, Public Offering, Lock-Up Agreement